Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release.

Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M.

Parkinsons Dis. 2014;2014:467131. doi: 10.1155/2014/467131. Epub 2014 Apr 1.

2.

The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study.

Wang Y, Sun S, Zhu S, Liu C, Liu Y, Di Q, Shang H, Ren Y, Lu C, Gordon MF, Juhel N, Chen S.

Transl Neurodegener. 2014 Jun 2;3:11. doi: 10.1186/2047-9158-3-11. eCollection 2014.

3.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.

Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317.

PMID:
20669317
4.

Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.

Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):759-66. doi: 10.1212/WNL.0b013e31822affb0. Epub 2011 Aug 10.

PMID:
21832218
5.

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10.

PMID:
21832216
6.

Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.

Thorlund K, Wu P, Druyts E, Eapen S, Mills EJ.

Neuropsychiatr Dis Treat. 2014 May 7;10:767-76. doi: 10.2147/NDT.S60061. eCollection 2014.

7.

Pramipexole extended release: in Parkinson's disease.

Chwieduk CM, Curran MP.

CNS Drugs. 2010 Apr;24(4):327-36. doi: 10.2165/11204570-000000000-00000. Review.

PMID:
20297857
8.

Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.

Takanashi M, Shimo Y, Hatano T, Oyama G, Hattori N.

Drug Res (Stuttg). 2013 Dec;63(12):639-43. doi: 10.1055/s-0033-1351257. Epub 2013 Jul 24.

PMID:
23884661
9.

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.

Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C; Pramipexole Switch Study Group.

Mov Disord. 2010 Oct 30;25(14):2326-32. doi: 10.1002/mds.23262.

PMID:
20669265
10.

Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.

Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V.

J Neurol Sci. 2003 Dec 15;216(1):81-7.

PMID:
14607306
11.

Rotigotine transdermal system for the treatment of Parkinson's disease.

Pham DQ, Nogid A.

Clin Ther. 2008 May;30(5):813-24. doi: 10.1016/j.clinthera.2008.05.007. Review.

PMID:
18555929
12.

Determination of minimal clinically important change in early and advanced Parkinson's disease.

Hauser RA, Auinger P; Parkinson Study Group.

Mov Disord. 2011 Apr;26(5):813-8. doi: 10.1002/mds.23638. Epub 2011 Mar 24.

PMID:
21437987
13.

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.

Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W; Pramipexole ER Studies Group.

Eur J Neurol. 2014 May;21(5):736-43.

14.

Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W.

Eur J Neurol. 2013 Jan;20(1):180-7. doi: 10.1111/j.1468-1331.2012.03822.x. Epub 2012 Jul 31.

PMID:
22845710
17.

Pramipexole for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002261. Review.

PMID:
10908540
18.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
19.

The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.

Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C.

Parkinsonism Relat Disord. 2001 Apr;7(2):115-120.

PMID:
11248592
20.

Pramipexole in patients with early Parkinson's disease.

Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, Korts D, Elvin A.

Clin Neuropharmacol. 1995 Aug;18(4):338-47.

PMID:
8665547
Items per page

Supplemental Content

Write to the Help Desk